Skip to main content

Lucas Svetlana's Form 4 filing

Jasper Therapeutics, Inc. (JSPR) · filed Sep 24, 2025

Accession no.
0001213900-25-091104
Filed
Sep 24, 2025
Trade date
Sep 22, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $48.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lucas SvetlanaCIK 0001781292Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 22, 2025Voting Common StockPPurchaseAcquired+20,000$2.43F1+$48,60020,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 22, 2025Voting Common StockPPurchaseAcquired+20,000–F1–20,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)